Sign Up to like & get
recommendations!
0
Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2437_10
Abstract: also been approved as adjuvant therapy for high risk stage III melanoma (2015). Results regarding adjuvant therapy with either nivolumab or pembrolizumab are expected in 2018. Combinations: Further developments in the field of melanoma are…
read more here.
Keywords:
combination;
lymphoma;
anti pd1;
radiotherapy localised ... See more keywords